#cormedix

CorMedix, Inc. (NYSE: CRMD): Q3 2019 Earnings Snapshot

— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year.

— Net sales dropped to $59.53 million from $372.5 million in the same period of last year

— Net loss before recognition of the deemed dividends was $5.3 million

— Operating…

CorMedix falls ahead of Q1 results; reporting after the bell today

Biopharmaceutical company CorMedix (CRMD) is set to report its first quarter 2019 results after the bell today. CorMedix stock had dropped about 4% at 3:00 PM ET. Market watchers expect the company to post a loss of 28 cents per share on revenue of $60,000 for the recently ended quarter.

CorMedix, which develops and commercializes therapeutic products for the prevention and treatment of…

Q4 Earnings Preview: All eyes on Neutrolin trial updates from CorMedix

Biopharma firm CorMedix (NYSE American: CRMD) has seen its shares skyrocket more than 500% in the last 12 months as investors are pinning their hopes on the positive LOCK trial results. Investors would be interested to know from the management how the ongoing discussions with the FDA regarding the phase 3 trial results and future course of action.

CorMedix is planning to report its fourth-quarter…

PEDEVCO (PED:ASE) and Cormedix (CRMD:ASE) Are Biggest Stock Gainers YTD on AMEX

Stockcalc – Free Trial

Have a free look inside the StockCalc website at www.stockcalc.com

I have used the analysis tools on the website stockcalc.com to generate some of the content of this blog post. These tools and reports are available for free at www.stockcalc.com/TopPicks.aspx.

Biggest Stock Gainers Year to Date on AMEX

Today we are looking at companies that have had the greatest…